Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioAge Labs (BIOA) Total Current Liabilities (2023 - 2026)

BioAge Labs' Total Current Liabilities history spans 3 years, with the latest figure at $20.1 million for Q4 2025.

  • On a quarterly basis, Total Current Liabilities fell 27.5% to $20.1 million in Q4 2025 year-over-year; TTM through Dec 2025 was $20.1 million, a 27.5% decrease, with the full-year FY2025 number at $20.1 million, down 27.5% from a year prior.
  • Total Current Liabilities hit $20.1 million in Q4 2025 for BioAge Labs, down from $24.5 million in the prior quarter.
  • Over the last five years, Total Current Liabilities for BIOA hit a ceiling of $58.2 million in Q4 2023 and a floor of $19.1 million in Q3 2024.
  • Historically, Total Current Liabilities has averaged $28.0 million across 3 years, with a median of $23.7 million in 2025.
  • Biggest five-year swings in Total Current Liabilities: tumbled 52.25% in 2024 and later grew 28.37% in 2025.
  • Tracing BIOA's Total Current Liabilities over 3 years: stood at $58.2 million in 2023, then tumbled by 52.25% to $27.8 million in 2024, then fell by 27.5% to $20.1 million in 2025.
  • Business Quant data shows Total Current Liabilities for BIOA at $20.1 million in Q4 2025, $24.5 million in Q3 2025, and $22.8 million in Q2 2025.